- Commenting on the approval, Seeking Alpha contributor and Egalet (OTC:EGLT) bull Bret Jensen says the FDA's decision not to include the "abuse deterrent" label for intranasal use despite the overwhelming Ad-Comm recommendation is yet another head-scratcher from the agency.
- The abuse-deterrent label was approved for IV and oral uses.
- He still thinks the drug sees solid sales and he bought more shares at $6.61.
- Gabelli downgrades to Hold.
- Shares -24% to $6.37.